Dual/multitargeted xanthone derivatives for Alzheimer's disease: where do we stand?

• Type: Article in International Scientific Journal
• Date: 2017

Authors

Cruz, MI (Author) Other; Honorina Cidade (Author) FFUP; Pinto, M (Author) Other

Journal

Title: Future Medicinal Chemistry

Vol. 9

Pages: 1611-1630

ISSN: 1756-8919

Publisher: Future Medicine Ltd.

Indexing

ISI Web of Knowledge - 24 Citations

Scopus - 23 Citations

Other information

Authenticus ID: P-00N-28V

DOI: 10.4155/fmc-2017-0086

Abstract (EN): To date, the current therapy for Alzheimer's disease (AD) based on acetylcholinesterase inhibitors is only symptomatic, being its efficacy limited. Hence, the recent research has been focused in the development of different pharmacological approaches. Here we discuss the potential of xanthone derivatives as new anti-Alzheimer agents. The interference of xanthone derivatives with acetylcholinesterase and other molecular targets and cellular mechanisms associated with AD have been recently systematically reported. Therefore, we report xanthones with anticholinesterase, monoamine oxidase and amyloid beta aggregation inhibitory activities as well as antioxidant properties, emphasizing xanthone derivatives with dual/multitarget activity as potential agents to treat AD. We also propose the structural features for these activities that may guide the design of new, more effective xanthone derivatives.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 20